View in EDS

NFATc1+CD31+CD45− circulating multipotent stem cells derived from human endocardium and their therapeutic potential.

Saved in:
Bibliographic Details
Title: NFATc1+CD31+CD45− circulating multipotent stem cells derived from human endocardium and their therapeutic potential.
Authors: Yang, Han-Mo1,2,3 (AUTHOR), Kim, Ju-Young1,2,3 (AUTHOR), Cho, Hyun-Jai1,2,3 (AUTHOR), Lee, Joo-Eun2,3 (AUTHOR), Jin, Sooryeonhwa2,3 (AUTHOR), Hur, Jin2,3 (AUTHOR), Kwon, Yoo-Wook2,3 (AUTHOR), Seong, Moon-Woo4 (AUTHOR), Choi, Eue-Keun1,3 (AUTHOR), Lee, Hae-Young1,3 (AUTHOR), Lee, Hyun-Seob5 (AUTHOR), Jeon, Mika2,3 (AUTHOR), Kim, Joonoh2,3 (AUTHOR), Yang, Jaeseok6 (AUTHOR), Oh, Seil1,3 (AUTHOR), Suh, Kyung-Suk7 (AUTHOR), Yoon, Sung-Soo1 (AUTHOR), Kim, Ki-Bong8 (AUTHOR), Oh, Byung-Hee1,3 (AUTHOR), Park, Young-Bae1,3 (AUTHOR)
Source: Biomaterials. Feb2020, Vol. 232, pN.PAG-N.PAG. 1p.
Subjects: Multipotent stem cells, Endocardium, Microsatellite repeats, Heart cells, Progenitor cells, Myocardial infarction, Atrial arrhythmias
Abstract: Many studies have shown the existence of cardiac stem cells in the myocardium and epicardial progenitor cells in the epicardium. However, the characteristics of stem cells in the endocardium has not been fully elucidated. In this study, we investigated the origin of newly identified cells in the blood and their therapeutic potential. The new population of cells, identified from human peripheral blood, was quite different from previously reported stem cells. These newly identified cells, which we named Circulating Multipotent Stem (CiMS) cells, were multipotent, and therefore differentiated into multiple lineages in vitro and in vivo. In order to determine the origin of these cells, we collected peripheral blood from a group of patients who underwent bone marrow, liver, heart, or kidney transplantation. We identified the endocardium as the origin of these cells because the Short Tandem Repeat profile of CiMS cells from the recipient had changed from the recipient's profile to the donor's profile after heart transplantation. CiMS cells significantly increased after stimuli to the endocardium, such as catheter ablation for arrhythmia or acute myocardial infarction. CiMS cells circulate in human peripheral blood and are easily obtainable, suggesting that these cells could be a promising tool for cell therapy. [ABSTRACT FROM AUTHOR]
Copyright of Biomaterials is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Many studies have shown the existence of cardiac stem cells in the myocardium and epicardial progenitor cells in the epicardium. However, the characteristics of stem cells in the endocardium has not been fully elucidated. In this study, we investigated the origin of newly identified cells in the blood and their therapeutic potential. The new population of cells, identified from human peripheral blood, was quite different from previously reported stem cells. These newly identified cells, which we named Circulating Multipotent Stem (CiMS) cells, were multipotent, and therefore differentiated into multiple lineages in vitro and in vivo. In order to determine the origin of these cells, we collected peripheral blood from a group of patients who underwent bone marrow, liver, heart, or kidney transplantation. We identified the endocardium as the origin of these cells because the Short Tandem Repeat profile of CiMS cells from the recipient had changed from the recipient's profile to the donor's profile after heart transplantation. CiMS cells significantly increased after stimuli to the endocardium, such as catheter ablation for arrhythmia or acute myocardial infarction. CiMS cells circulate in human peripheral blood and are easily obtainable, suggesting that these cells could be a promising tool for cell therapy. [ABSTRACT FROM AUTHOR]
ISSN:01429612
DOI:10.1016/j.biomaterials.2019.119674